Working with luminal and triple-negative breast cancer cell line models, in organoids and in tumor-bearing mice, we show that co-inhibition of PI3K and SHP2 potently counteracts both acquired and intrinsic resistance to PI3K inhibitors. Here, PIK3CA is linked to neoplasm.